Table of Contents
PITTSBURGH — Mylan Inc. is launching morphine sulfate extended-release tablets, an opioid analgesic for the treatment of moderate to severe pain.
The company said its Mylan Pharmaceuticals Inc. subsidiary has received final approval from the Food and Drug Administration for morphine sulfate ER tablets in strengths of 15 mg, 30 mg, 60 mg, 100 mg and 200 mg. The prescription medication is shipping immediately.
According to Mylan, the product is the generic version of Purdue Pharma’s MS Contin medication for pain management.
Morphine sulfate ER tablets had U.S. sales of about $173 million for the 12 months ended June 30, according to IMS Health figures reported by Mylan.
